Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taysha Gene TherapiesTSHA -2.71%33 Current Ratio is 17.76 as of Jun. 2026, which is 263% above its 10-year median of 4.89. GuruFocus rates TSHA with a GF Score™ of 33/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Taysha Gene Therapies ranks better than 90.7% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Taysha Gene Therapies's current ratio for the quarter that ended in Jun. 2026 was 17.76.
Taysha Gene Therapies has a current ratio of 17.76. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Taysha Gene Therapies's Current Ratio or its related term are showing as below:
TSHA'
s Current Ratio Range Over the Past 10 Years
Min: 0.1 Med: 4.89 Max: 36.17
Current: 17.76
During the past 7 years, Taysha Gene Therapies's highest Current Ratio was 36.17. The lowest was 0.10. And the median was 4.89.
TSHA's Current Ratio is ranked better than 90.7% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs TSHA: 17.76
Taysha Gene Therapies (NAS:TSHA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Taysha Gene Therapies Current Ratio Related Terms
Taysha Gene Therapies Current Ratio Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Current Ratio distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a Current Ratio of 17.76 as of Jun. 2026. This is 263% above median its historical median of 4.89. Over the past decade, Taysha Gene Therapies' Current Ratio has ranged from 0.10 to 36.17. According to the industry distribution chart, Taysha Gene Therapies ranks #131 out of 1409 companies in the Biotechnology industry, placing it in the top 9.3%.
Is Taysha Gene Therapies' Current Ratio too high?
Taysha Gene Therapies' current Current Ratio of 17.76 is 263% above median its 10-year median of 4.89. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 36.17. The Biotechnology industry median Current Ratio is 3.89. Taysha Gene Therapies' value of 17.76 is 356.6% above this industry median. Based on the distribution chart, Taysha Gene Therapies ranks #131 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' Current Ratio compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #131 out of 1409 companies for Current Ratio. This places Taysha Gene Therapies in the top 9% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Taysha Gene Therapies' value of 17.76 is 356.6% above this benchmark. Historically, Taysha Gene Therapies' own Current Ratio has ranged from 0.10 to 36.17 over the past decade. While the company's 10-year median is 4.89 vs. the industry median of 3.89, Taysha Gene Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taysha Gene Therapies's current Current Ratio of 17.76 is 356.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current Current Ratio is 17.76, which is 263% above median its own 10-year median of 4.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current Current Ratio is 17.76, which is 263% above median its 10-year median of 4.89 and 356.6% above the Biotechnology industry median of 3.89. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current Current Ratio is 17.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
Current Ratio: 17.76 (263% above median its 10-year median of 4.89)
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
Industry Position: 356.6% above the Biotechnology median (#131 of 1409)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
